Related Experiment Videos
Variable K(+) channel subunit dysfunction in inherited mutations of KCNA1.
Ruth Rea1, Alexander Spauschus, Louise H Eunson
1University Department of Clinical Neurology, Institute of Neurology, UCL, Queen Square, London WC1N 3BG, UK.
The Journal of Physiology
|January 5, 2002
Summary
Mutations in the KCNA1 gene cause episodic ataxia type 1 (EA1) and related disorders. This study reveals how specific KCNA1 mutations disrupt potassium channel assembly, trafficking, and function, explaining varied disease severity.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Mutations in KCNA1, encoding the hKv1.1 potassium channel subunit, are linked to episodic ataxia type 1 (EA1).
- These mutations manifest in diverse neurological phenotypes, including neuromyotonia, seizures, and drug-resistant EA1.
Purpose of the Study:
- To investigate the functional consequences of specific KCNA1 mutations on hKv1.1 channel assembly, trafficking, gating, and permeation.
- To correlate molecular defects with the observed clinical variability in patients with EA1 and related disorders.
Main Methods:
- Co-expression of mutant and wild-type hKv1.1 subunits in Xenopus oocytes.
- Electrophysiological recordings and pharmacological analysis to assess channel function.
- Confocal laser scanning microscopy of EGFP-tagged subunits to evaluate membrane trafficking and expression levels.
Main Results:
- The R417stop mutation severely impairs tetramerization and membrane targeting, correlating with drug-resistant EA1.
- Mutations V404I (typical EA1) and P244H (neuromyotonia) primarily altered channel kinetics without affecting assembly or trafficking.
- Mutations T226R and A242P showed intermediate effects, impacting both assembly/trafficking and kinetics.
Conclusions:
- The wide spectrum of KCNA1 mutation phenotypes is explained by diverse molecular mechanisms affecting channel assembly, trafficking, and kinetics.
- Understanding these genotype-phenotype correlations is crucial for diagnosing and managing EA1 and related channelopathies.